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Abstract 
The tremendous boost in the next generation 
sequencing and in the “omics” technologies makes it 
possible to characterize human gut microbiome —the 
collective genomes of the microbial community that 
reside in our gastrointestinal tract—. While some of 
these microorganisms are considered as essential 
regulators of our immune system, some others can cause 
several diseases such as Inflammatory Bowel Diseases 
(IBD), diabetes, and cancer. IBD, comprising Crohn’s 
disease and ulcerative colitis, is a gut related disorder 
where the deviations from the “healthy” gut microbiome 
are considered to be associated with IBD. Although 
some existing studies attempt to unveal the composition 
and functional capacity of the gut microbiome in relation 
to IBD diseases, a comprehensive picture of the gut 
microbiome in IBD patients is far from being complete. 
Due to the complexity of metagenomic studies, the 
applications of the state-of-the-art machine learning 
techniques became popular to address a wide range of 
questions in the field of metagenomic data analysis. In 
this regard, using IBD associated metagenomics dataset, 
this study utilizes both supervised and unsupervised 
machine learning algorithms, i) to generate a 
classification model that aids IBD diagnosis, ii) to 
discover IBD-associated biomarkers, iii) to find 
subgroups of IBD patients using k-means and 
hierarchical clustering. To deal with the high 
dimensionality of features, we applied robust feature 
selection algorithms such as Conditional Mutual 
Information Maximization (CMIM), Fast Correlation 
Based Filter (FCBF), min redundancy max relevance 
(mRMR) and Extreme Gradient Boosting (XGBoost). In 
our experiments with 10-fold cross validation, XGBoost 
had a considerable effect in terms of minimizing the 
microbiota used for the diagnosis of IBD and thus 
reducing the cost and time. We observed that compared 
to the single classifiers, ensemble methods such as 
kNN+logitboost resulted in better performance measures 
for the classification of IBD.  
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1. Introduction 
Human gut microbiota is a complex community of 
microorganisms including trillions of bacteria that 
populate in our gastrointestinal tract. While some of 
these microorganisms are considered as essential 
regulators of our immune system, some others can infect 
human body and cause diseases such as IBD, diabetes, 
obesity, cancer, autoimmune and neurodegenerative 
disorders. In this respect, deciphering the function and 
composition of our gut microbiome —the collective 
genomes of the microbial community that reside in 
human gut—is crucial. 
In recent decades, the rapid advances in next 
generation sequencing (NGS) technologies enabled to 
generate millions to billions of reads in a single run. 
Metagenomic NGS approaches, which permit to analyze 
the entire genomic content of a sample and provide 
taxonomic and functional profiles of microbial 
communities; accelerated the discovery of the human gut 
microbiome. Since our gut microbiome is modulated via 
human-microbiome symbiosis, the metagenomic 
analysis of gut microbiome provides novel insights 
regarding the effect of human gut microbiota on human 
physiology and diseases [1-5].  
IBD, comprising Crohn’s disease (CD) and 
ulcerative colitis (UC), is a gut related disorder that 
affects the intestinal tract. Deviations from the “healthy” 
gut microbiome that occur due to environmental effects, 
dietary and genetic mutations are considered to be 
associated with IBD. Hence, the metagenomic analysis 
of human gut microbiome helps to illuminate IBD 
development mechanisms. Since the aetiology of IBD is 
not fully understood and symptoms are complex, the 
design of new tools that make use of the available 
human gut metagenome data is essential for the 
diagnosis of IBD. In this respect, machine learning (ML) 
is well suited to obtain a diagnostic model using IBD-
associated metagenomics dataset.      
Mosotto et.al. [6] suggested to use machine learning 
algorithms to diagnose CD and UC patients among a 
group of paediatric inflammatory bowel disease patients. 
Using endoscopic and histological data, they achieved 
82.7% CD/UC discrimination accuracy. Pasolli et. al. [7] 
attempted to classify the cases (patients) and the controls 
(healthy samples) using the metagenomic-associated 
datasets of Cirrhosis, Colorectal Cancer, IBD, Obesity 
and Type 2 diabetes. They tested the performances of the 
support vector machines (SVM), random forest (RF) 
classifiers and also evaluated Lasso and elastic net 
regularized multiple logistic regression. Due to the low 
number of CD patients, they combined CD and UC 
patients together and their predictive model achieved the 
area under the curve (AUC) of 0.914 for discrimination 
of IBD patients using the species abundance information 
as a feature vector. Yazdani et. al. [8] investigated the 
major changes in microbiome protein family abundances 
between IBD patients and healthy subjects. Wei et. al. 
[9] proposed a risk prediction scheme for IBD. Using 
genome-wide association study data obtained from 
17,000 CD cases, 13,000 UC cases, and 22,000 controls, 
they obtained AUCs of 0.86 and 0.83 for CD and UC, 
respectively. Wingfield et. al. [10] presented a method 
for the stratification of IBD presence, and IBD subtype 
from a bacterial census of the intestinal microbiome. Via 
using a hybrid classifier of multi layer perceptron (MLP) 
and SVM, they obtained AUCs of 0.70 and 0.74 for CD 
and UC, respectively. 
In our previous work [11], for the diagnosis of IBD, 
we analyzed IBD-associated metagenomics dataset using 
state-of-art machine learning algorithms, ensemble 
methods and shrinkage methods including ridge 
regression, Lasso [12] and Elastic Net [13]. Our best 
models achieved AUC of 0.919, 87.7 % accuracy and 
F1-measure of 83.7 %.       
In this study, firstly, we attempt to identify IBD-
associated biomarkers via utilizing robust feature 
selection algorithms such as Conditional Mutual 
Information Maximization (CMIM), Fast Correlation 
Based Filter (FCBF), Min redundancy Max relevance 
(mRMR) and Extreme Gradient Boosting (XGBoost). 
Using state-of-the art machine learning algortihms and 
ensemble classification methods such as SVM, Decision 
tree, RF, Adaboost, and Logitboost, we assess the 
performance of our reduced metagenomics dataset. We 
evaluate our models systematically and extensively 
using several metrics. Secondly, we aim to find 
subgroups of IBD patients via applying k-means and 
hierarchical clustering on IBD-associated metagenomics 
dataset. Since the symptoms and the treatments of IBD 
are complex, the precise identification of IBD subgroups 
could provide a valuable insight for discovering 
individualized therapy targets and will pave the way 
towards personalized medicine applications. 
Additionally, we perform Principal Compenent Analysis 
(PCA) to obtain the underlying structure of IBD 
metagenomics data. In summary, this study utilizes both 
supervised and unsupervised machine learning 
algorithms, i) to generate a classification model that aids 
IBD diagnosis, ii) to investigate potential pathobionts of 
IBD, and iii) to find out subgroups of IBD patients.       
The rest of this paper is organized as follows. 
Section 2 presents the machine learning algorithms and 
feature selection methods that we used to obtain a 
diagnostic model of IBD, to identify IBD biomarkers of 
human gut microbiota, and to discover the subgroups of 
IBD patients. Section 3 highlights our findings and 
provides an extensive evaluation of our method. Section 
4 presents a discussion of our findings. Section 5 
concludes the paper and summarizes avenues for further 
research. 
2. Materials and Methods 
In this study, we aim to develop a classification model to 
aid IBD diagnosis and to discover IBD-associated 
biomarkers using metagenomics data. In this respect, the 
raw microbiome DNA sequencing data of 148 IBD 
patients and 234 control samples were fetched from 
MetaHit project [14] and categorized into disease states 
based on the associated metadata. Using MetaPhlAn2 
taxonomic classification tool, each DNA sequence was 
assigned to its microbial species of origin (taxa). 
Consequently, the microbial diversity (i.e. which 
microorganisms exist in what relative abundance) of the 
gut microbiome for each sample was revealed. As shown 
in Figure 1, our IBD-associated metagenomics dataset 
included the sequence reads from 1455 taxa for 382 
samples. This dataset is used to develop, train, test and 
validate a machine-learning model to diagnose IBD. 
 
 
Figure 1. Illustration of the metagenomics dataset 
 
Our methodology can be summarized in the 
following steps: i) feature selection to identify the most 
informative IBD-associated biomarkers, ii) model 
construction to classify IBD patients and control 
samples, followed by the assessment of the generated 
models using extensive evaluation metrics, iii) 
unsupervised learning to detect subgroups of IBD 
patients and control samples. Figure 2 shows the details 
of these three steps. 
2.1 Feature Selection 
In metagenomics studies, the number of predictors 
(number of taxa) is much more than the number of 
observations. In this respect, feature selection 
methodologies such as mRMR [15], Lasso [7], Elastic 
Net [13] and iterative sure select algorithm [15] have 
been extensively applied to reduce the number of taxa 
(species). In this work, we proposed to apply 
Conditional Mutual Information Maximization (CMIM), 
Fast Correlation Based Filter (FCBF) and Min 
Redundancy Max Relevance (mRMR), Extreme 
Gradient Boosting (XGBoost) feature selection 
algorithms on metagenomics dataset, which have not 
been used in this domain before.  CMIM first ranks the 
features according to their conditional entropy and 
mutual information with the class to predict; and then 
selects the feature if it carries additional information. 
Similarly, FCBF ranks features based on their mutual 
information with the class to predict; and then removes 
the features whose mutual information is less than a 
predefined threshold. mRMR selects the features that 
have the most correlation with a class to predict 
(relevance) and the less correlation between themselves 
(redundancy). In XGBoost feature selection, the more an 
attribute is used to make key decisions with decision 
trees, the higher relative importance it gets. Via applying 
a predefined threshold, one can select top ranked 
features in CMIM, FCBF, and XGBoost.  
2.2 Model Construction 
In order to discriminate IBD samples from controls, we 
construct a range of machine learning models using 
different classification algorithms such as RF, Desicion 
Tree, Logitboost, Adaboost, SVM and stacking 
ensemble classifiers. Python scikit-learn library [16] is 
used for the implementation of these algorithms. 
Prediction performances of our models were 
evaluated by using Accuracy, F1 Score, and AUC 
measures. Accuracy is a widely used performance 
evaluation metric and a reliable measure for the balanced 
datasets. Since we have an uneven class distribution in 
our dataset, to evaluate the performance of our models 
we also utilize other metrics such as F1 score and the 
area under the ROC curve (AUC). F1-score, which 
denotes the harmonic mean of presicion and recall, is a 
better performance metric, when someone seeks a 
balance between precision and recall, and when there is 
an uneven class distribution (large number of actual 
negatives). AUC is commonly used as a summary 
measure of diagnostic accuracy. In real life examples, 
there is an overlap between the test results of positive 
and negative examples. AUC shows how the recall vs. 
precision relationship changes as we change the 
threshold or the cut-off value for identifying a positive. 
2.3 Unsupervised Learning 
The relationship between the samples and the species is 
important to understand the disease development 
mechanisms, to detect subgroups of IBD patients and 
controls. In order to visualize and analyze this 
relationship, we performed three unsupervised methods: 
k-means clustering, PCA, and hierarchical clustering 
using euclidian distance.  
3. Experiments 
3.1 Classification 
Our IBD-associated metagenomics dataset included the 
sequence reads from 1455 taxa for 382 samples. Firstly, 
we removed the irrelevant and redundant features 
(species) using the feature selection strategies including 
FCBF, CMIM, mRMR and XGBoost. Applied on IBD-
associated metagenomics dataset, Figure 3 illustrates the 
numbers of selected features using different feature 
selection algorithms. While 56 of 1455 features are 
selected by at least one of the four different feature 
selection algorithms, 10 features are selected by all of 
the tested feature selection algorithms.  
 
 
 
 
Figure 2. Schematic representation of our methodology. Feature selection, model construction and unsupervised 
learning processes are shown in red, blue and green, respectively. 
Secondly, we optimize the parameters “c” and “gamma” 
for SVM, “number of tree” for Desicion tree, Random 
Forest, Logitboost and Adaboost. Following the 
identification of optimal parameters and features, we 
validate and test our models using 10-fold cross 
validation. Lastly, we assessed the performance of our 
models using the features that are selected by each 
feature selection algorithm independently, and also using 
the union of the features, which are chosen by at least 
one of the four different feature selection algorithms. 
Our models are extensively evaluated using several 
evaluation metrics, as summarized in Figure 4. We 
observed that ensemble methods such as kNN (k nearest 
neighbor) + Logitboost resulted in better performance 
measures for the classification of IBD patients vs control 
samples. For the diagnosis of IBD patients, significant 
results, i.e., 0,947 AUC, 0,872 F1-score and 90,05% 
accuracy were obtained by using 24 features (selected 
using XGBoost) and stacking with k means and 
logitboost classifier.  
Figure 4 highlights the improvement in terms of 
performance measures once the feature selection 
strategies are applied (Fig. 4a-d, 4f). For all tested 
classifiers, XGBoost feature selection algortihm resulted 
in higher performance values with only 24 features (Fig 
4d). The feature selection methods, especially XGBoost, 
is found to have a considerable effect in terms of 
minimizing the microbiota used for the diagnosis of IBD 
and thus reducing the cost and time. Also, the union of 
the selected features (56 features) had a considerable 
performance improvement (Fig. 4f). 
 
 
Figure 3. Numbers of selected features (species) 
using different feature selection algorithms 
 
Figure 5 illustrates the comparision of the 
performances of all tested classification algorithms on 
IBD-associated metagenomics dataset in terms of feature 
selection methods. As shown in Figure 5, the application 
of the selected feature selection algorithms increased the 
performances of the classification algorithms. The union 
of the selected features (56 features) shows the best 
performance in terms of F-measure. In terms of ROC 
area, the classification algorithms including RF, 
Logitboost, Adaboost and ensemble classifiers resulted 
in higher performances (>0.9) on our IBD associated 
metagenomics dataset.  
(a)                                                                                        (b) 
             
(c)                                                                                        (d) 
           
(e)                                                                                         (f) 
             
Figure 4. Performance evaluations of different classifiers on IBD metagenomics dataset, using 10-fold cross 
validation with parameter optimization, after applying  (a) FCBF, (b) CMIM, (c) mRMR, (d) XGBoost feature 
selection techniques, (e) without feature selection, (f) union of FCBF, CMIM, mRMR and XGBoost. 
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Figure 5.  Comparisons of the performances of different classifiers and different feature selection methods, in 
terms of (a) Area under ROC, (b) F-Measure, and (c) Accuracy 
 
3.2 Feature importances and their correlations 
The identification of critical species, the ones having a 
key role in IBD disease development, can constitute new 
targets for the development of probiotics to correct 
microbiota aberrations [17-20]. To this end, we analyzed 
the XGBoost importance scores of the species and found 
that some of the identified species are related with IBD 
development mechanisms. Figure 6 shows the feature 
importances of the 24 features (species) that are selected 
via XGBoost. In Figure 6a, while the Y axis corresponds 
to feature ids of the features, X axis corresponds to 
relative importances which are calculated using 
information gain. Figure 6b lists the high scoring 24 
features with their species names.  
In order to analyze the pairwise correlations of these 
selected species, we use Spearman’s rank correlation 
coefficient and illustrate these relations using a heatmap 
in Figure 6c. This analysis resulted in only two moderate 
positive correlations between the two species namely 
Eubacterium Hallii - Coprococcus Comes and 
Eubacterium Hallii – Dorea formicigenerans. 
3.3 Grouping control and IBD samples via K means 
clustering algorithm  
We investigate that if we subgrouped the samples 
according to their health situations, whether these 
subgroups have a direct relationship with some species. 
In this respect, we use K means clustering algortihm to 
subgroup samples. 
 K means is an unsupervised learning algorithm 
that groups samples by minimizing the error inside the 
clusters and maximizing the distance between the 
clusters. We select the number of clusters using elbow 
method. In this method, the point where the decline in 
the error slows down indicates the optimum number of 
clusters. As shown in Figure 7, using euclidian distance, 
optimum 12 subgroups among controls and 7 subgroups 
among IBD samples were discovered. Figure 8 
illustrates the identified control and IBD subgroups and 
the presence of the species in each of these subgroups. 
It can be concluded from Figure 8 that even though 
the samples were divided into subgroups, a single 
species has no direct effect on the development of IBD. 
Nevertheless, there are a few observations that we can 
make: i) Bifidobacterium-bifidum (shown in orange) is 
mainly observed in IBD subgroups (ibd 01, 06, 07) and 
not in the control subgroups; ii) Bifidobacterium 
adolecentis is observed in ibd06 and ibd07 and in none 
of the control groups except cont04; iii) Bacteroides 
stercoris (shown in gray) is present in five of the ibd 
groups (ibd 01-05), where there is no significanct 
presence of Bifidobacterium adolecentis. Consecutively, 
Bacteroides stercoris (shown in gray) is not present in 
ibd06 and ibd07, where there is high presence of 
Bifidobacterium adolecentis. 
3.4 Discrimination of data via Principal Compenent 
Analysis (PCA) 
In order to analyze whether the metagenomic data can be 
divided into two clusters representing control and IBD 
samples, the first two principal compenents of data were 
obtained using PCA as an unsupervised learning 
approach.  
PCA is used for reducing the dimension of the 
feature space in such a way that the principal 
compenents in the new feature space are orthogonal to 
each other. The PCA results in Figure 9 show that better 
seperation is observed between control and IBD classes 
when PCA is performed with 24 top scoring features 
(Figure 9b, 9d). Also, it is important to point out that this 
result is achieved only with 24 species instead of 1455 
species (Figure 9a, 9c). However, the new feature space, 
reduced via PCA, does not have a significant 
contribution in terms of classification performance. It is 
important to note that since PCA maps the data into a 
new feature space, the original feature information is lost 
during this process. Thus, PCA analysis does not allow 
for any biomarker discovery, as the species information 
is no longer represented in the new mapped feature 
space. 
 
 
(a)                                       (b) 
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Figure 6.  (a) The features that have high relative importance scores in XGBoost. While the Y axis corresponds to 
feature ids of these features, X axis corresponds to relative importance values of corresponding features. The sum of 
relative importance of all 1455 features is equals to 1. (b) List of the species that have top 24 importance scores for 
IBD. (c) Pairwise Spearman rank correlations of top 24 important species. 
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Figure 7. Selection of the optimum number of subgroups for (a) controls and (b) IBD patients. 
 
 
148: Lachnospiraceae bacterium GCF 000218445 
  52: Bacteroides xylanisolvens 
173: Ruminococcus bromii 
145: Dorea formicigenerans 
  47: Bacteroides stercoris 
139: Butyrivibrio crossotus 
129: Eubacterium hallii 
160: Roseburia inulinivorans 
135: Blautia hydrogenotrophica 
  58: Parabacteroides distasonis 
383: Clostridiales Family XIII Incertae Sedis unclassified 
  75:Alistipes finegoldii 
      
131:Eubacterium rectale 
  56:Odoribacter splanchnicus  
  55:Coprobacter fastidiosus  
245:Akkermansia muciniphila 
155:Lachnospiraceae bacterium GCF 000242155 
  76:Alistipes indistinctus  
154:Lachnospiraceae bacterium GCF 000185525 
417:Peptostreptococcus stomatis 
  35:Bacteroides dorei  
168:Faecalibacterium prausnitzii  
137:Ruminococcus obeum  
142:Coprococcus comes 
 
 
Figure 8. Illustration of control and IBD subgroups (best viewed in color). 
 
3.5 Hierarchical Clustering of reduced IBD dataset 
In order to better visualize the relationship between the 
samples and the species, we also performed hierarchical 
clustering using euclidian distance and Ward variance 
minimization algorithm as the linkage method. The 
heatmap in Figure 10 is obtained using all samples and 
top scoring 24 species. Colors represent raw based z-
scores of all samples. While the black color indicates 
read counts just around the mean, the lighter colors 
denote the read counts of 1 to 4 standart deviations 
above the mean. The first column specifies class labels, 
i.e., IBD patients and healthy samples are shown in red 
and blue, respectively. The areas that are restricted with 
red boxes could suggest the relative abundance of the 
corresponding species in these subgroups. For example, 
the red boxes in 5th and 6th columns indicate excessive 
levels of Lachnospiraceae bacterium and Bacteroides 
stercoris in the corresponding IBD subgroups.  
4. Discussion 
In this study, we compared the performances of machine 
learning methods including SVM, RF Adaboost, 
Logitboost, Decision tree and some ensemble methods 
on a dataset, which is obtained from MetaHit project 
containing species as features of the human gut 
microbiota of IBD patients and controls. To deal with 
the high dimensionality of features, we apply some 
feature selection methods including FCBF, CMIM, 
mRMR and XGBoost. We analyzed the XGBoost 
importance scores of the species and the top scoring 
species are found to be related with IBD development 
mechanisms. Among the species that we identified as 
potential IBD biomarkers (listed in Figure 6b), 
Bacteroides xylanisolvens [21] and Eubacterium hallii 
[22] are considered as candidate next-generation 
probiotics, promoting gut health. Other selected features 
of bacterial taxa, Lachnospiraceae, Parabacteroides, 
Blautia, Butyrivibrio, Dorea, Ruminococcus, and 
Roseburia are previously identified as potential 
biomarkers of IBD [23]. However, discovering these 
markers and potential therapeutic agents either requires 
laborious wet-lab processes or they can be only 
discovered at genus level. Our study enabled a shotgun 
discovery of multiple biomarkers via applying a careful 
feature selection. 
Our proposed feature selection procedures achieve 
unprecedented performance using a feature subset of 
smaller cardinality, compared to the current state-of-the-
art. Using a similar IBD-associated metagenomics 
dataset which is obtained from MetaHIT Project, 
Passolli et. al. [7] achieved 0.809% accuracy, 0.81 
recall, 0.89 AUC, 0.78 precision and 0.78 F1 score, 
when they reduced the number of species into 441 using 
gini index. In this work, unprecedented results such as 
91.623% accuracy, 0.933 AUC, 0.89 F1 score, 0.903 
precision and 0.878 recall were obtained by using the 
union for selected features (a total of 56 features) and 
stacking with K means and logitboost classifier. Using 
only the XGBoost feature selection algorithm (24 
features) with the same classifier achieves 90.05% 
accuracy, 0.947 AUC, 0.872 F1 score, 0.872 Precision, 
and 0.872 recall. These selected species could be 
suggested as potential IBD-biomarkers of human gut 
microbiata. Hence, this study leads to a framework for 
precise biomarker discovery, which enables targeting 
minimal number of diagnostic/theurepathic markers with 
large effect sizes. Such metagenomic drug discovery 
tools would imply a potential for narrowing the spectrum 
intervention, which can be feasible with the current 
pharmaceutical technology. 
5. Conclusions 
Gut microbiota can affect the host immune system 
and metabolism, which are central to program many 
aspects of host activities. Metagenomic analysis of 
human microbiome reveals significant phenotypical 
signals, such as disease, as microbiome is modulated via 
human-microbiome symbiosis. Since the accuracy of 
diagnosis in IBD is key to prompt an effective treatment, 
there is an utmost need to develop a novel classification 
technique that can expedite IBD diagnosis. This study 
utilizes several supervised and unsupervised machine 
learning algorithms on an IBD associated metagenomics 
data to aid diagnostic accuracy, to investigate potential 
pathobionts of IBD, and to find out which subset of 
microbiota is more informative than other taxa applying 
some of the state-of-the art feature selection methods. 
Overall, this paper provides a blueprint for the use of 
advanced feature selection and machine learning 
techniques on disease-associated metagenomics data. 
 
(a)                (b) 
  
      (c)                (d) 
  
Figure 9. Principal component analysis of (a, c) all 
IBD-associated metagenomics dataset, (b, d) reduced 
dataset that includes features for top scoring 24 species. 
 
 
Figure 10. Z-score normalization (raw based) and Euclidian distance based hierarchical clustering. Ward variance 
minimization algorithm was used as a linkage method. The side bar on the left handside (named class) indicates the 
referred diagnosis: IBD patients and healthy samples are shown in red and blue, respectively. The dendograms are 
plotted on the top and left side of the figure. 
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